He Ministry of Health of the Province of Buenos Aires reported this Friday that “Argentine scientists are developing the protein vaccine ARVAC Cecilia Grierson against COVID-19, designed to protect against variants of SARS-CoV-2 circulating in the region, including a bivalent version against Ómicron”.
“ARVAC Cecilia Grierson It is an initial development of CONICET, the National University of San Martín and the Cassará Laboratory, added to the joint effort of more than 20 public and private institutions in the country”, detailed from the health portfolio.
The study is carried out in centers in the province of Buenos Aires authorized by the Ministry of Health and it has the approval of the competent national and provincial authorities in the area, clarified press spokesmen for the Government House.
According to those responsible for the initiative, “the results of the first stage of the investigation have shown that this vaccine is safe.”
“In addition, the preliminary values of the immune response are promising. Now the most advanced phase of the development of the vaccine must continue, which, if the efficacy and safety results are verified, will be presented to the ANMAT to request its approval as a booster vaccine,” they added.
If you want to participate and register, your data “will be used exclusively for the call for this investigation”, assured from the provincial government.
Requirements
- Having received 2 or 3 doses of a vaccine against Covid-19
- Be over 18 years of age.
- Live in Greater Buenos Aires, La Plata or Mar del Plata
The selected people will subsequently receive information about the closest research center to their home.
2023-05-12 22:41:01
#volunteers #participate #study #Argentine #vaccine #COVID19 #Info #Blanco #Sobre #Negro
